Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome

Histopathology

Volumn 61, Issue 2, 2012, Pages 200-211

  Pülhorn, Heinke ^a   Herrmann, Martin ^a   Harms, Harry ^b,e   Jung, Andreas ^c   Baumann, Irith ^d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d Department of Pathology   (Germany)

^e Institute of Pathology   (Germany)

Author keywords

Apoptosis; Cytotoxic T cell expansion; Myelodysplastic syndrome

Indexed keywords

ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; T CELL RESTRICTED INTRACELLULAR ANTIGEN 1; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER GRADING; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DONOR; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; NICK END LABELING; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; APOPTOSIS; AUTOIMMUNITY; BASE SEQUENCE; BONE MARROW CELLS; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; GENE REARRANGEMENT, T-LYMPHOCYTE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84864390842     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04209.x     Document Type: Article

References (44)

1. Fialkow PJ, Singer JW, Raskind WH et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N. Engl. J. Med. 1987; 317; 468-473.
2. Morita Y, Matsuda M, Hanamoto H et al. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system. Clin. Immunol. 2004; 113; 109-116.
3. Claessens YE, Bouscary D, Dupont JM et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002; 99; 1594-1601.
4. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk. Res. 1998; 22; 1123-1136.
5. Kitagawa M, Yamaguchi S et al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998; 12; 486-492.
6. Raza A, Gezer S, Mundle S et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86; 268-276.
7. Widell S, Hellstrom-Lindberg E, Kock Y, Lindberg M, Ost A, Hast R. Peripheral blood neutrophil morphology reflects bone marrow dysplasia in myelodysplastic syndromes. Am. J. Hematol. 1995; 49; 115-120.
8. Cantú Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in childhood (EWOG-MDS). Ann. Hematol. 2005; 84; 429-433.
9. Kuriyama K, Miyazaki Y, Arimura K et al. Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes. Leuk. Res. 1995; 19; 121-125.
10. Emura I. High incidence of apoptosis in peripheral blood of myelodysplastic syndrome patients determined by Papanicolaou-stained preparations. Lab. Hematol. 2003; 9; 42-46.
11. Amin HM, Jilani I, Estey EH et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003; 102; 1866-1868.
12. Mundle SD, Ali A, Cartlidge JD et al. Evidence for involvement of tumor necrosis factor-α in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am. J. Hematol. 1999; 60; 36-47.
13. Shinohara K, Muraki K et al. Increased levels of soluble tumor necrosis factor receptors in patients with aplastic anemia and myelodysplastic syndrome. Am. J. Hematol. 2002; 65; 326-327.
14. Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor necrosisfactor-alpha by bone marrow T lymphocytes is essential in causing bone marrowfailure in patients with aplastic anemia. Eur. J. Haematol. 2004; 73; 10-16.
15. Campioni D, Secchiero P, Corallini F et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am. J. Pathol. 2005; 166; 557-563.
16. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro haemopoiesis. Blood 2001; 98; 3058-3065.
17. Voulgarelis M, Giannouli S et al. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur. J. Clin. Invest. 2004; 34; 690-700.
18. Tsuda H, Yamasaki H. Type I and type II T-cell profiles in aplastic anemia and refractory anemia. Am. J. Hematol. 2000; 64; 271-274.
19. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivodominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004; 364; 355-364.
20. Matsutani T, Yoshioka T, Tsuruta Y et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk. Res. 2003; 27; 305-312.
21. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100; 3639-3645.
22. Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br. J. Haematol. 2003; 122; 617-622.
23. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk. Res. 2001; 25; 1075-1083.
24. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp. Hematol. 2001; 29; 1270-1277.
25. b profiles. Br. J. Haematol. 1998; 102; 1314-1322.
26. Higushi R. Principles and applications for DNA amplification. New York: Stockton Press, 1992; 31-38.
27. Diss TC, Watts M, Pan LX, Burke M, Linch D, Isaacson PG. The polymerase chain reaction in the demonstration of monoclonality in T cell lymphomas. J. Clin. Pathol. 1995; 48; 1045.
28. Harms H, Gunzer U. Combined local color and texture analysis of stained cells. Image Proc. 1986; 33; 364-376.
29. Fuehrer M, Rampf U et al. Immunosuppressive therapy for aplastic anaemia in children: a more severe disease predicts better survival. Blood 2005; 106; 2102-2104.
30. Bouscary D, de VosJ, Guesnu M et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11; 839-845.
31. Gersuk GM, Beckham C et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol. 1998; 103; 176-188.
32. Stadler M, Germing U, Kliche KO et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk nyelodysplastic syndrome. Leukemia 2004; 18; 460-465.
33. Sloand EM, Mainwaring L, Fuhrer M et al. Preferential suppression of trisomy 8compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106; 841-851.
34. Broliden PA, Dahl IM, Hast R et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndrome. Haematologica 2006; 91; 667-670.
35. Baumann I, Scheid C, Koref MS, Swindell R, Stern P, Testa NG. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic snydrome. Exp. Hematol. 2002; 30; 1405-1411.
36. Young NS. The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood 1992; 79; 1385-1392.
37. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358; 155-157.
38. Kordasti SY, Afzali B, Lim Z et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br. J. Haematol. 2009; 145; 64-72.
39. Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011; 25; 226-235.
40. Benites BD, Traina F, Duarte Ada S, Lorand-Metze IG, Costa FF, Saad ST. Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia. Eur. J. Haematol. 2010; 84; 525-530.
41. Olnes MJ, Sloand EM. Targeting immune dysregulation in myleodysplastic syndromes. JAMA 2011; 305; 814-819.
42. Epling-Burnette PK, Painter JS, Rollison DE et al. Prevalence and clinical association of cloncal T-cell expansions in myelodysplastic syndrome. Leukemia 2007; 21; 659-667.
43. Fozza C, Continti S, Galleu A et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp. Hematol. 2009; 37; 947-955.
44. Plasilova M, Risitano A, Maciejewski JP. Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic disease. Hematology 2003; 8; 173-181.